Clinical Trial Update: 3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing multiple Hib-MenCY-TT and Hib-MenC-TT vaccine formulations to a licensed meningococcal vaccine in infants aged 2-4 months; study compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Haemophilus Influenzae Type Disease
• Neisseria Meningitidis Disease

Drugs mentioned

• Hib-MenC-TT vaccine (1 formulation) (Haemophilus influenzae type b meningococcal serogroup C tetanus toxoid conjugate vaccine)
• Hib-MenCY-TT vaccine (3 formulations) (Haemophilus influenzae type b meningococcal serogroups C and Y tetanus toxoid conjugate vaccine)
• Licensed Meningococcal Serogroup C Conjugate Vaccine (Neisseria meningitidis serogroup C meningococcal conjugate vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Haemophilus Influenzae Type b, Neisseria Meningitidis | Phase 2 | Status: COMPLETED | Results posted: 2012-07-23